Larimar Therapeutics (Nasdaq:LRMR) - Aandelenkoers, Nieuws & Analyse

LRMR Overzicht aandelen

LRMR fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Volatiele aandelenkoers in de afgelopen 3 maanden

Larimar Therapeutics, Inc. Concurrenten

enGene Holdings

NasdaqCM:ENGN

US$438.4m

Tango Therapeutics

NasdaqGM:TNGX

US$412.5m

Orchard Therapeutics

NasdaqCM:ORTX

US$380.1m

Prime Medicine

NasdaqGM:PRME

US$426.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Larimar Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$6.64
52 Week Hoogtepunt	US$13.68
52 Week Laag	US$3.19
Bèta	0.71
11 maand verandering	-17.10%
3 maanden verandering	-17.52%
1 Jaar Verandering	103.06%
33 jaar verandering	-27.27%
5 jaar verandering	n/a
Verandering sinds IPO	-46.02%

Recent nieuws en updates

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Oct 07

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Aug 09

Larimar Therapeutics: More Data Still Needed

Jul 15

Recent updates

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Oct 07

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Aug 09

Larimar Therapeutics: More Data Still Needed

Jul 15

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08

Rendement voor aandeelhouders

	LRMR	US Biotechs	US Markt
7D	9.2%	4.3%	1.6%
1Y	103.1%	18.8%	32.3%

Rendement versus industrie: LRMR overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 18.8 % opleverde.

Rendement versus markt: LRMR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 32.3 %.

Prijsvolatiliteit

Is LRMR's price volatile compared to industry and market?
LRMR volatility
LRMR Average Weekly Movement	12.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van LRMR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van LRMR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	42	Carole Ben-Maimon	www.larimartx.com

Larimar Therapeutics, Inc., een biotechnologiebedrijf in een klinische fase, richt zich op de ontwikkeling van behandelingen voor zeldzame ziekten met behulp van zijn nieuwe celpenetrerende peptidetechnologieplatform. De belangrijkste productkandidaat is CTI-1601, dat zich in Fase 2 van de OLE klinische studie bevindt voor de behandeling van ataxie van Friedreich, een zeldzame, progressieve en dodelijke genetische ziekte. Larimar Therapeutics, Inc. is gevestigd in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Larimar Therapeutics zich tot de beurswaarde?
LRMR fundamentele statistieken
Marktkapitalisatie	US$394.32m
Inkomsten(TTM)	-US$64.77m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-6.5x

Koers/Winstverhouding

Is LRMR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LRMR resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$64.77m
Inkomsten	-US$64.77m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.02
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde LRMR op de lange termijn?

Bekijk historische prestaties en vergelijking

LRMR Overzicht aandelen

Risicoanalyse

Larimar Therapeutics, Inc. Concurrenten

NasdaqCM:ENGN

US$438.4m

NasdaqGM:TNGX

US$412.5m

NasdaqCM:ORTX

US$380.1m

NasdaqGM:PRME

US$426.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Larimar Therapeutics: More Data Still Needed

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

Recent updates

Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Larimar Therapeutics: More Data Still Needed

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Price target decreased to US$10.59

High number of new and inexperienced directors

Laramar Therapeutics issued patent for lead pipeline candidate

CEO, President & Director recently bought US$100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics prices ~$70M stock offering

Price target increased to US$6.23

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

Larimar Therapeutics GAAP EPS of -$0.47

Price target increased to US$5.88

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Price target decreased to US$13.50

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Independent Director recently bought US$496k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

New 90-day low: US$17.75

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

New 90-day high: US$22.50

Larimar Therapeutics reports Q3 results

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high: US$18.91

New 90-day high - US$16.00

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index